| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5464826 | LILLY | Method of treating tumors in mammals with 2',2'-difluoronucleosides |
Nov, 2012
(11 years ago) | |
|
US5464826 (Pediatric) | LILLY | Method of treating tumors in mammals with 2',2'-difluoronucleosides |
May, 2013
(10 years ago) | |
Gemzar is owned by Lilly.
Gemzar contains Gemcitabine Hydrochloride.
Gemzar has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Gemzar are:
- US5464826
- US5464826*PED
Gemzar was authorised for market use on 15 May, 1996.
Gemzar is available in injectable;injection dosage forms.
Gemzar can be used as method of treating susceptible neoplasms in mammals.
The generics of Gemzar are possible to be released after 07 May, 2013.
Drugs and Companies using GEMCITABINE HYDROCHLORIDE ingredient
Market Authorisation Date: 15 May, 1996
Treatment: Method of treating susceptible neoplasms in mammals
Dosage: INJECTABLE;INJECTION
How can I launch a generic of GEMZAR before it's drug patent expiration?
More Information on Dosage
GEMZAR family patents
